FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

SEQUENT Share Price Target

Sequent Scientific Ltd.
NSE: SEQUENT | BSE: 512529 | ISIN: INE807F01027 | Sector: Pharmaceuticals and health care


5/5 (1 Ratings)
SEQUENT Share Price *
84.5 +1.4 (1.68%)
* (quote may be delayed)

2 SEQUENT share price target reports by brokerages below. See what is analyst's view on SEQUENT share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.

You can also find SEQUENT share price target tomorrow or next week from SEQUENT discussion forum.

SEQUENT Share Price Forecast - Consensus
No. of reports in last year
No. of analysts
Average Consensus Forecast
Consensus Potential

SEQUENT Share Price Target - Broker Reports - 2020

Price @ Call: 83.13
Target: 97

SEQUENT Share Price Target - Broker Reports - 2019

Price @ Call: 68.02
Target: 115
With the API business gaining significant proportion over the last one year, SSL gets a strong earnings base over which the formulations business growth will continue to be built. The API business has further steam left and can continue to grow in high-teens to mid-20s, driven by an improved product/geography mix. Currently, about 57% of the API revenue comes from regulated markets which continue to improve as the company starts filing more products in the US. In addition to geography mix, pricing dynamics in the API space are also supportive. On the formulations front, the company is expecting growth, driven by approval of new registrations. The larger part of growth in formulations segment will be driven by monetization of the injectable pipeline in the US and other regulated markets which should begin FY21 onwards. The first injectable filing for the US markets will happen in FY21
... Read more

Price @ Call: 69.39
Target: 116
On a rough cut basis, in FY19, Topline will see a steady rise wherein Topline is expected to touch Rs 1042 crs in FY19E. On the bottomline level we expect the company to record a PAT of Rs 50 crs in FY19E. Thus on a conservative basis, SeQuent should record a EPS of Rs 2.04 for FY19E. For FY20E and FY21E our expectation is that earnings traction for SeQuent would continue to be strong wherein we expect a EPS of Rs 3 and Rs 4.18 respectively.
... Read more

  • SEQUENT - Share Price Target Potential

    Nirmal Bang9714.33%
  • SEQUENT Share Price Target Today- Technical Pivot Points (Classic)

    Upside Target 385.77
    Upside Target 284.83
    Upside Target 183.97
    Downside Target 182.17
    Downside Target 281.23
    Downside Target 380.37
  • SEQUENT Share Price Target weekly- Technical Pivot Points (Classic)

    Upside Target 389.15
    Upside Target 287.3
    Upside Target 185.2
    Downside Target 181.25
    Downside Target 279.4
    Downside Target 377.3
  • SEQUENT Share Price Target monthly- Technical Pivot Points (Classic)

    Upside Target 396.02
    Upside Target 288.98
    Upside Target 183.07
    Downside Target 170.12
    Downside Target 263.08
    Downside Target 357.17
  • SEQUENT Share Price Target today- Technical Pivot Points (Fibonacci)

    Upside Target 384.83
    Upside Target 284.15
    Upside Target 183.72
    Downside Target 182.35
    Downside Target 281.92
    Downside Target 381.23
  • SEQUENT Share Price Target weekly- Technical Pivot Points (Fibonacci)

    Upside Target 387.3
    Upside Target 285.79
    Upside Target 184.86
    Downside Target 181.84
    Downside Target 280.91
    Downside Target 379.4
  • SEQUENT Share Price Target monthly- Technical Pivot Points (Fibonacci)

    Upside Target 388.98
    Upside Target 284.04
    Upside Target 180.98
    Downside Target 171.09
    Downside Target 268.03
    Downside Target 363.08
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
FrontPage © 2020